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Background: Current recommendations from scientific societies to support revascularization over optimal medical therapy (OMT) to prolong 
survival in stable coronary artery disease (CAD) originate from trials conducted in the 1970’s.Our objective was therefore to compare OMT to 
revascularization strategies of the past and present.
methods: We identified RCT’s that compared at-least two of medical therapy (MT), PCI or CABG. Contemporary treatments included CABG with LIMA, 
PCI with stents and OMT. Their historic counterparts were CABG with vein grafts, PTCA and old MT (CASS era) .The outcome of interest was mortality. 
We performed random effects pair-wise and network meta-analysis.
results: We identified 46 eligible RCT’s. OMT showed a trend towards reduced mortality compared to historical CABG (HR 1*45, 95% CI 0*88 to 
2*42) or historical MT (HR 1*57, 95% CI 0*97 to 2*57). OMT was similar to PCI (HR 0*92, 95% CI 0*78 to 1*07) or PTCA (HR 0*91, 95% CI 0*75 
to 1*12). Contemporary CABG was statistically better than OMT (HR 0*80, 95% CI 0*69 to 0*93) and even more so than old MT (HR 0*51, 95% CI 
0*31 to 0*80). All contemporary revascularization therapies were superior to historical therapies used in the CASS era.
conclusions and relevance: OMT, if had been used in the CASS era, would have resulted in decreased mortality in medically treated patients 
as compared with CABG. The current guidelines do not accurately reflect the remarkable improvements in CAD therapeutics and maybe potentially 
misleading.
